ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

CHRS Coherus BioSciences Inc

2.25
0.08 (3.69%)
2024年5月4日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Coherus BioSciences Inc CHRS NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
0.08 3.69% 2.25 08:12:45
始値 安値 高値 終値 前日終値
2.20 2.19 2.3219 2.27 2.17
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/5/0205:30GLOBECoherus to Report First Quarter 2024 Financial Results on..
2024/4/2423:02GLOBECoherus Announces Presentation at the 2024 American Society..
2024/4/0821:30GLOBECoherus Presents Preclinical Data for CHS-1000, a Novel..
2024/3/1405:01GLOBECoherus BioSciences Reports Fourth Quarter, Full Year 2023..
2024/3/0606:01GLOBECoherus to Report Fourth Quarter and Full Year 2023..
2024/3/0420:22EDGAR2Form 8-K - Current report
2024/3/0415:00GLOBECoherus Completes Divestiture of Ophthalmology Franchise
2024/2/2407:33GLOBECoherus BioSciences Announces New Employment Inducement..
2024/2/2307:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2307:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
2024/2/2306:59EDGAR2Form 8-K - Current report
2024/2/2122:30GLOBECoherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and..
2024/2/0522:09EDGAR2Form 8-K - Current report
2024/2/0522:00GLOBECoherus Amends Term Loan Agreement with Pharmakon Advisors,..
2024/1/2410:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/2410:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/2222:01EDGAR2Form 8-K - Current report
2024/1/2215:59DJNSandoz to Acquire Cimerli Business from Coherus for $170..
2024/1/2215:15GLOBECoherus Announces Agreement to Divest Ophthalmology..
2024/1/1906:05GLOBECoherus Presents Positive Phase 2 Clinical Data on..
2024/1/1011:41EDGAR2Form 8-K - Current report
2024/1/1011:39EDGAR2Form 8-K - Current report
2024/1/1009:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/0908:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/0507:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/0507:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/0422:00PRNUSINOVIO and Coherus Announce Clinical Collaboration to..
2024/1/0406:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/0323:00GLOBECoherus BioSciences Management to Present at the 42nd Annual..
2024/1/0222:29GLOBECoherus Announces U.S. Launch of LOQTORZI™
2023/12/2723:15APSAnother Biotech Massively Outperforming Broader Equities
2023/12/2720:08IHMARKETNEWSWall Street Highlights: Apple Appeals Watch Ban, Tesla to..
2023/12/2706:43DJNCoherus BioSciences Gets FDA OK for Udenyca Injector
2023/12/2706:01GLOBECoherus Announces FDA Approval of UDENYCA ONBODY™, a Novel..
2023/12/2307:00GLOBECoherus BioSciences Announces New Employment Inducement..
2023/12/1606:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/1206:13EDGAR2Form 8-K - Current report
2023/12/1122:30GLOBECoherus Announces Updated NCCN Clinical Practice Guidelines..
2023/12/0807:55GLOBECoherus BioSciences Announces CFO Transition Plans
2023/12/0807:16EDGAR2Form 8-K - Current report
2023/12/0618:00GLOBECoherus Presents Phase 1/2 Clinical Data on Casdozokitug, a..
2023/11/2901:16GLOBECoherus and Junshi Biosciences Announce Publication of..
2023/11/2806:03EDGAR2Form 8-K - Current report
2023/11/1320:07EDGAR2Form 8-K/A - Current report: [Amend]
2023/11/0706:35EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/0706:31EDGAR2Form 8-K - Current report
2023/11/0706:07GLOBECoherus BioSciences Reports Third Quarter 2023 Financial..
2023/11/0620:07EDGAR2Form 8-K/A - Current report: [Amend]
2023/11/0321:30GLOBECoherus Presents Data from Next-generation Immuno-oncology..
2023/11/0309:00GLOBECoherus BioSciences to Participate at Upcoming November..

最近閲覧した銘柄

Delayed Upgrade Clock